12/04/2025
🚨 CMS & NIH Official Announcement for Medicare Beneficiaries
The Centers for Medicare & Medicaid Services (CMS), in partnership with the National Institutes of Health (NIH), has launched the Medicare Genomic Screening Initiative (MGSI).
This limited pilot program provides comprehensive genetic screening at $0 cost to qualified Medicare Part B beneficiaries.
What this means for you:
• Early detection of hereditary cancer risks (BRCA1/2, Lynch syndrome)
• Alzheimer's/Dementia predisposition screening (APOE ε4)
• Cardiovascular genetic markers for heart disease prevention
• Pharmacogenetic testing for medication safety
Key Details:
✅ 100% covered by Medicare - No out-of-pocket costs
✅ At-home test kit shipped directly to you
✅ Results reviewed by board-certified genetic counselors
✅ Shared with your primary care physician for follow-up
Limitations:
• Enrollment closes December 31, 2024
• Must complete eligibility questionnaire first
Real Patient Experience:
_"The MGSI test found a genetic mutation that my regular doctor missed. Early detection gave me life-saving options I wouldn't have had otherwise."_ - Linda R., Medicare beneficiary
📋 To check your eligibility (takes 2 minutes):
